CD274 and esophageal squamous cell carcinoma: Therefore, this study aimed to evaluate the cost-effectiveness of serplulimab plus chemotherapy as the first-line treatment for previously untreated, PD-L1-positive (CPS ≥ 1) advanced ESCC from the perspective of Chinese healthcare system.